Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CGP-53153 is a steroidal inhibitor of 5 alpha-reductase (IC50s: 36 and 262 nM in rat and human prostatic tissue).
产品描述 | CGP-53153 is a steroidal inhibitor of 5 alpha-reductase (IC50s: 36 and 262 nM in rat and human prostatic tissue). |
靶点活性 | 5α reductase (human):262 nM , 5α reductase (rat):36 nM |
体外活性 | CGP-53153 competitively inhibits rat microsomal 5 alpha-reductase from the prostate (IC50: 36 nM) compared to the reference compound finasteride (IC50: 11 nM). |
体内活性 | CGP-53153 (0.01 mg/kg, p.o.) can significantly reduce T-propionate-mediated prostate growth. CGP-53153 significantly reduces prostate weight at 3 and 10 mg/kg by 31% and 37%, respectively. Treatment for 12 weeks with both CGP-53153 reduces prostate volume by more than 70% in individual dogs. Neither body weight nor the weight of any organ tested is affected by CGP-53153. |
分子量 | 383.53 |
分子式 | C23H33N3O2 |
CAS No. | 149281-19-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CGP-53153 149281-19-6 Others CGP 53153 CGP53153 Inhibitor inhibitor inhibit